Lyophilized (Long-term) -20C (-4F) Freezer
BPC 157 Therapy: Targeting Angiogenesis and Nitric Oxide's Cytotoxic and Damaging Actions, but Maintaining, Promoting, or Recovering Their Essential Protective Functions
Cross-compound receptor-occupancy percentages are deliberately not compared here: occupancy (pRO) is a modeled inference, not a measurement, and Willard 2020 cautions that "calculating pRO values has caveats." These EC50s measure functional potency, not binding affinity
At Perfect B in Doral, BPC-157 is delivered inside a structured process: we assess your goals and history, build a protocol and tell you what to take and why, deliver the complete kit with a day-by-day guide, and then measure and adjust
Also dosing is uncertain
Preclinical studies have demonstrated no significant toxicity even at doses far exceeding therapeutic ranges